ArticleCureus2025
Impact of Patent Foramen Ovale on Ischemic Stroke Outcomes in Patients Aged 65 and Older: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction This study evaluated the clinical characteristics, outcomes, and management implications associated with patent foramen ovale (PFO) in patients aged 65 and older who presented with ischemic stroke at a single center. Methods This retrospective study included patients aged 65 and older who were admitted with ischemic stroke between 2017 and 2019 and were followed for three years. Patients were categorized based on the presence or absence of a PFO identified during the index hospitalization. Outcomes included events during the index admission and ischemic stroke readmissions during follow-up. Continuous variables were analyzed using the Student's t-test, and categorical variables were compared using the Pearson Chi-square test. Binary logistic regression was used to identify independent predictors of ischemic stroke recurrence. Results A total of 1,090 patients were included. Of these, 116 patients (10.6%) had a PFO and 974 (89.4%) did not. The mean age was 74.8 years in the PFO group and 75.9 years in the non-PFO group. Comorbidities were similar between groups. The three-year ischemic stroke readmission rate was 8.9% in the PFO group and 11.2% in the non-PFO group (P = 0.36). Hypertension was independently associated with ischemic stroke recurrence (Odds Ratio = 3.88; 95% CI: 1.1-17; P = 0.04). No patients with PFO underwent closure during follow-up. Conclusion Among patients aged 65 and older admitted with ischemic stroke, the presence of PFO was not associated with differences in three-year stroke readmission rates or length of stay during the index hospitalization. In this cohort, ischemic stroke recurrence was associated with hypertension rather than PFO status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.